|Articles|June 19, 2020
NeurologyLive Friday 5 — June 19, 2020
Author(s)NeurologyLive® Staff
Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 19, 2020.
Advertisement
Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
1: Peer Exchange: SPR1NT Trial of Onasemnogene Abeparvovec for SMA
The SPR1NT phase 3 clinical trial—pivotal in pushing the concept of newborn screening for SMA—assessing onasemnogene abeparvovec-xioi in children less than 6 weeks of age is discussed, as well as a recently released integrated safety report.
2: Progressive MS: The CMSC 2020 Whitaker Lecture
Scott Newsome, DO, MSCS, FAAN, president of CMSC, offers his perspective on the 2020 Whitaker Lecture from Peter Calabresi, MD.
3: AHS 2020: Erenumab Shows Sustainable Efficacy in Refractory Episodic Migraine
Over a 2-year stretch, change in monthly migraine days from the double-blind treatment period baseline was sustained in those treated with erenumab.
4: Insights: Gastroparesis and Uptake of Oral Medication for Parkinson Disease
Peter LeWitt, MD, offers an expert perspective on gastroparesis and its influence on the uptake of oral medication for Parkinson disease.
5: Intranasal DHE Meets Primary Objectives in Treatment of Acute Migraine
Impel NeuroPharma, the agent’s developer, is on target for submission of a new drug application for the treatment in the second half of 2020.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
- NeurologyLive® Friday 5 — September 12, 2025
September 12th 2025
- Expanding the Alzheimer Drug Development Pipeline
September 12th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive
1
MDA and PPMD Release Consensus Guidelines for Safe and Equitable Use of Gene Therapy in Duchenne
2
Expanding the Alzheimer Drug Development Pipeline
3
DORAs Carry Lower Real-World Abuse, New Phase 3 Argus Data, RAP-219 Meets Primary End Point
4
Shared Decision-Making and Ethics in Complex Neurology Clinical Research: Paul Ford, PhD
5